TITLE

Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma

AUTHOR(S)
Breuhahn, Kai; Schirmacher, Peter; Qin Su
PUB. DATE
March 2008
SOURCE
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1690
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Constitutive activation of the insulin-like growth factor (IGF)-signaling axis is frequently observed in human hepatocellular carcinoma (HCC). Especially the over-expression of the fetal growth factor IGF-II, IGF-I receptor (IGF-IR), and cytoplasmic downstream effectors such as insulin-receptor substrates (IRS) contribute to proliferation, anti-apoptosis, and invasive behavior. This review focuses on the relevant alterations in this signaling pathway and independent in vivo models that support the central role IGF-II signaling during HCC development and progression. Since this pathway has become the center of interest as a target for potential anti-cancer therapy in many types of malignancies, various experimental strategies have been developed, including neutralizing antibodies and selective receptor kinase inhibitors, with respect to the specific and efficient reduction of oncogenic IGF-II/IGF-IR-signaling.
ACCESSION #
31436359

 

Related Articles

  • Upregulation of the Insulin Receptor and Type I Insulin-Like Growth Factor Receptor Are Early Events in Hepatocarcinogenesis. ALEEM, EIMAN; NEHRBASS, DIRK; KLIMEK, FRITZ; MAYER, DORIS; BANNASCH, PETER // Toxicologic Pathology;Apr2011, Vol. 39 Issue 3, p524 

    The molecular mechanisms underlying the development of hepatocellular carcinoma (HCC) are not yet fully understood. Preneoplastic foci of altered hepatocytes regularly precede HCC in various species. The predominant earliest type of foci of altered hepatocytes, the glycogen storage focus (GSF),...

  • Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. Arbuthnot, Patrick; Thompson, Liam Jed; Piscaglia, Anna C. // World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1670 

    Primary liver cancer is the fifth most common malignancy in the world and is a leading cause of cancer-related mortality. Available treatment for hepatocellular carcinoma (HCC), the commonest primary liver cancer, is rarely curative and there is a need to develop therapy that is more effective....

  • Molecular Targeted Therapy of Hepatocellular Carcinoma -- Results of the First Clinical Studies. Wiedmann, M. W.; M�ssner, J. // Current Cancer Drug Targets;Jul2011, Vol. 11 Issue 6, p714 

    No abstract available.

  • Up-Regulation of MicroRNA-190b Plays a Role for Decreased IGF-1 That Induces Insulin Resistance in Human Hepatocellular Carcinoma. Hung, Tzu-Min; Ho, Cheng-Maw; Liu, Yen-Chun; Lee, Jia-Ling; Liao, Yow-Rong; Wu, Yao-Ming; Ho, Ming-Chih; Chen, Chien-Hung; Lai, Hong-Shiee; Lee, Po-Huang // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Background & Aims: Insulin-like growth factor, (IGF)-1, is produced mainly by the liver and plays important roles in promoting growth and regulating metabolism. Previous study reported that development of hepatocellular carcinoma (HCC) was accompanied by a significant reduction in serum IGF-1...

  • Insulin-like growth factor-II: new roles for an old actor. Cianfarani, Stefano // Frontiers in Endocrinology;Oct2012, Vol. 3, p1 

    Insulin-like growth factor-II (IGF-II), traditionally considered as a growth factor implicated in growth of fetal tissues and cancer cells, is now emerging as a potential metabolic regulator. The aim of this overview is to provide the available evidence, obtained in both experimental conditions...

  • Novel therapeutic approaches for hepatocellulcar carcinoma: Fact and fiction. Yuan-Yuan Zhang; Hua-Xiang Xia, Harry; Keeffe, Emmet B. // World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1641 

    Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for 80%-90% of this class of malignancy. So far, understanding of its pathogenesis and effective therapeutic methods are rather limited. In this issue, 11 invited review articles are published to address current...

  • microRNA Involvement in Hepatocellular Carcinoma. Negrini, Massimo; Gramantieri, Laura; Sabbioni, Silvia; Croce, Carlo M. // Anti-Cancer Agents in Medicinal Chemistry;2011, Vol. 11 Issue 6, p500 

    The role of microRNAs (miRNAs) in human tumorigenesis has been demonstrated by gene profiling and functional studies. In hepatocellular carcinoma (HCC), consistently deregulated miRNAs were identified. Their aberrant expression revealed relations shared with other types of cancer and others...

  • Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma. Nambotin, Sarah B.; Wands, Jack R.; Kim, Miran // Anti-Cancer Agents in Medicinal Chemistry;2011, Vol. 11 Issue 6, p549 

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. However, there is little known about targeted therapeutics for the treatment of this devastating tumor. Among the growth factor signaling cascades deregulated in HCC, evidences suggest that the...

  • The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules. Ward, Colin W.; Garrett, Thomas P. J. // BMC Bioinformatics;2001, Vol. 2, p4 

    Background: Leucine-rich repeats are one of the more common modules found in proteins. The leucine-rich repeat consensus motif is LxxLxLxxNxLxxLxxLxxLxx- where the first 11-12 residues are highly conserved and the remainder of the repeat can vary in size Leucine-rich repeat proteins have been...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics